Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Relypsa Picks DSM As Contract Producer
by Michael McCoy
May 26, 2014
| A version of this story appeared in
Volume 92, Issue 21
The biotech firm Relypsa has signed a multiyear agreement under which DSM Fine Chemicals will manufacture patiromer, the active ingredient in Relypsa’s lead drug candidate. Patiromer is an ion-exchange resin that helps reduce phosphorus buildup in patients with chronic kidney disease. DSM rival Lanxess is the sole manufacturer of patiromer named in Relypsa’s pending New Drug Application. However, Relypsa plans to add DSM as a second manufacturer in the event of U.S. approval.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X